Does the media favor CRDL or ARDX?

In the previous week, Ardelyx had 12 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 15 mentions for Ardelyx and 3 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.47 beat Ardelyx's score of 0.01 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, IVA or CRDL?

Cardiol Therapeutics has lower revenue, but higher earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 154.86 -$400.67M N/A N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A

Is IVA or CRDL more profitable?

Inventiva's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Cardiol Therapeutics N/A -180.44% -140.28%

Does the media prefer IVA or CRDL?

In the previous week, Inventiva had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Inventiva and 3 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.47 beat Inventiva's score of 0.20 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiol Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, CRDL or GLAS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Glass House Brands N/A N/A N/A N/A N/A

Is CRDL or GLAS more profitable?

Glass House Brands' return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Glass House Brands N/A N/A N/A

Does the media prefer CRDL or GLAS?

In the previous week, Glass House Brands had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Glass House Brands and 3 mentions for Cardiol Therapeutics. Glass House Brands' average media sentiment score of 1.10 beat Cardiol Therapeutics' score of 0.47 indicating that Glass House Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glass House Brands 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRDL or COLL?

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 3 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.47 beat Collegium Pharmaceutical's score of -0.31 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Collegium Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Cardiol Therapeutics (CRDL) Competitors

$1.88 +0.02 (+0.81%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.93 +0.05 (+2.72%)

As of 09/18/2026 07:30 PM Eastern

Compare

CRDL vs. ARDX, IVA, GLAS, GYRE, and COLL

Should you buy Cardiol Therapeutics stock or one of its competitors? Cardiol Therapeutics's main competitors and comparable companies include Ardelyx (ARDX), Inventiva (IVA), Glass House Brands (GLAS), Gyre Therapeutics (GYRE), and Collegium Pharmaceutical (COLL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cardiol Therapeutics compare to Ardelyx?

Cardiol Therapeutics (NASDAQ:CRDL) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

In the previous week, Ardelyx had 12 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 15 mentions for Ardelyx and 3 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.47 beat Ardelyx's score of 0.01 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardiol Therapeutics has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Ardelyx	$407.32M	2.09	-$61.60M	-$0.22	N/A

Cardiol Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 433.33%. Ardelyx has a consensus price target of $13.90, suggesting a potential upside of 306.43%. Given Cardiol Therapeutics' higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Cardiol Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Ardelyx's return on equity of -36.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Ardelyx	-12.35%	-36.00%	-10.77%

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ardelyx beats Cardiol Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Inventiva?

Inventiva (NASDAQ:IVA) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

19.1% of Inventiva shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Inventiva had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Inventiva and 3 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.47 beat Inventiva's score of 0.20 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiol Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inventiva presently has a consensus target price of $15.75, indicating a potential upside of 316.67%. Cardiol Therapeutics has a consensus target price of $10.00, indicating a potential upside of 433.33%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Inventiva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cardiol Therapeutics has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	154.86	-$400.67M	N/A	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

Inventiva's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-180.44%	-140.28%

Inventiva has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Summary

Inventiva beats Cardiol Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Glass House Brands?

Cardiol Therapeutics (NASDAQ:CRDL) and Glass House Brands (NYSE:GLAS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Glass House Brands had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Glass House Brands and 3 mentions for Cardiol Therapeutics. Glass House Brands' average media sentiment score of 1.10 beat Cardiol Therapeutics' score of 0.47 indicating that Glass House Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glass House Brands	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Glass House Brands	N/A	N/A	N/A	N/A	N/A

12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Glass House Brands' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Glass House Brands	N/A	N/A	N/A

Cardiol Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 433.33%. Glass House Brands has a consensus target price of $16.00, indicating a potential upside of 102.92%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cardiol Therapeutics beats Glass House Brands on 5 of the 9 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Gyre Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, Cardiol Therapeutics had 3 more articles in the media than Gyre Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 0 mentions for Gyre Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.47 beat Gyre Therapeutics' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Gyre Therapeutics	Neutral

Cardiol Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Gyre Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Gyre Therapeutics	$116.59M	7.22	$5.03M	-$0.21	N/A

Cardiol Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 433.33%. Gyre Therapeutics has a consensus price target of $16.00, suggesting a potential upside of 111.92%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Cardiol Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -15.47%. Gyre Therapeutics' return on equity of -6.57% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

Summary

Gyre Therapeutics beats Cardiol Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Collegium Pharmaceutical?

Cardiol Therapeutics (NASDAQ:CRDL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 5.93% compared to Cardiol Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 3 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.47 beat Collegium Pharmaceutical's score of -0.31 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Collegium Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardiol Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 433.33%. Collegium Pharmaceutical has a consensus target price of $48.50, indicating a potential upside of 113.00%. Given Cardiol Therapeutics' higher probable upside, research analysts plainly believe Cardiol Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Collegium Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Collegium Pharmaceutical has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Collegium Pharmaceutical	$780.57M	0.95	$62.87M	$1.24	18.36

Summary

Collegium Pharmaceutical beats Cardiol Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDL vs. The Competition

Export

Metric	Cardiol Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$217.83M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-7.50	792.21	274.93	25.38
Price / Sales	N/A	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	17.05	10.53	10.46	6.33
Net Income	-$24.20M	$2.82B	$3.49B	$358.33M
7 Day Performance	-6.02%	1.69%	0.59%	1.12%
1 Month Performance	-4.34%	0.83%	-2.01%	-2.67%
1 Year Performance	67.41%	3.90%	18.09%	6.01%

Cardiol Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDL Cardiol Therapeutics	2.656 of 5 stars	$1.88 +0.8%	$10.00 +433.3%	+68.9%	$217.83M	N/A	N/A	18	News Coverage
ARDX Ardelyx	3.0265 of 5 stars	$3.40 -3.6%	$13.90 +309.4%	-46.7%	$846M	$407.32M	N/A	489	News Coverage
IVA Inventiva	2.5812 of 5 stars	$3.84 -1.2%	$15.38 +300.9%	-30.3%	$798.84M	$4.48M	N/A	73	Upcoming Earnings Analyst Forecast
GLAS Glass House Brands	3.6136 of 5 stars	$8.17 +0.9%	$16.00 +95.8%	N/A	$765.88M	N/A	N/A	357	Positive News Short Interest Decrease
GYRE Gyre Therapeutics	1.7718 of 5 stars	$6.51 -2.8%	$16.00 +146.0%	-1.8%	$731.06M	$116.59M	N/A	618	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDL) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. ARDX, IVA, GLAS, GYRE, and COLL

How does Cardiol Therapeutics compare to Ardelyx?

Summary

How does Cardiol Therapeutics compare to Inventiva?

Summary

How does Cardiol Therapeutics compare to Glass House Brands?

Summary

How does Cardiol Therapeutics compare to Gyre Therapeutics?

Summary

How does Cardiol Therapeutics compare to Collegium Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. ARDX, IVA, GLAS, GYRE, and COLL

How does Cardiol Therapeutics compare to Ardelyx?

Does the media favor CRDL or ARDX?

Which has preferable earnings and valuation, CRDL or ARDX?

Do analysts recommend CRDL or ARDX?

Which has more risk & volatility, CRDL or ARDX?

Is CRDL or ARDX more profitable?

Do institutionals & insiders have more ownership in CRDL or ARDX?

Summary

How does Cardiol Therapeutics compare to Inventiva?

Do insiders & institutionals hold more shares of IVA or CRDL?

Does the media prefer IVA or CRDL?

Do analysts recommend IVA or CRDL?

Which has stronger earnings and valuation, IVA or CRDL?

Is IVA or CRDL more profitable?

Which has more risk & volatility, IVA or CRDL?

Summary

How does Cardiol Therapeutics compare to Glass House Brands?

Does the media prefer CRDL or GLAS?

Which has higher valuation & earnings, CRDL or GLAS?

Do institutionals & insiders hold more shares of CRDL or GLAS?

Is CRDL or GLAS more profitable?

Do analysts recommend CRDL or GLAS?

Summary

How does Cardiol Therapeutics compare to Gyre Therapeutics?

Does the media prefer CRDL or GYRE?

Which has more risk and volatility, CRDL or GYRE?

Do insiders & institutionals hold more shares of CRDL or GYRE?

Which has preferable earnings & valuation, CRDL or GYRE?

Do analysts rate CRDL or GYRE?

Is CRDL or GYRE more profitable?

Summary

How does Cardiol Therapeutics compare to Collegium Pharmaceutical?

Do insiders and institutionals hold more shares of CRDL or COLL?

Which has more volatility & risk, CRDL or COLL?

Is CRDL or COLL more profitable?

Does the media favor CRDL or COLL?

Do analysts prefer CRDL or COLL?

Which has better valuation and earnings, CRDL or COLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools